Earticle

초록

영어

From decades ago, pancreatic islet transplantation has received major spotlights from many researchers and practitioners to be the most favorable treatment for Type 1 Diabetes (T1D); however, a major obstacle of current islet transplantation procedure is generally recognized as an islet graft rejection by the recipient’s immune system. As studied and reviewed many times, immunosuppressive drugs are showing promising but still limited results on organ and cell transplantations.
Also, in our previous studies, we have shown that PEGylation method along with Tacrolimus (FK506) could improve in certain extends, protection of transplanted islets from the rejection. Using Anti-CD154 monoclonal antibody (MR1 mAb) to block the costimulatory pathway of T-cell activation has been a successful method to prevent graft rejections. Though the importance and effectiveness of immunosuppressive drugs and mAb therapy were promising, their complications in high doses have interfered with their actual clinical uses. In this study, we have implemented the usage of MR1 to further suppress the host immune response in addition to PEGylation and FK506. After 300 Islets Equivalents (IEQ) were transplanted under left kidneys of C57BL/6 mice, MR1 was injected on 0, 2, 4, 6 days after Tx, while FK506 was given every day.

키워드

저자

• Sung Woo HONG [ Dept. of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, 151-742, Korea. ]
• Jee-Heon JEONG [ College of Pharmacy, Seoul National University, Seoul 151-742, South Korea. ]
• Simmyung YOOK [ College of Pharmacy, Seoul National University, Seoul 151-742, South Korea. ]
• Yoonsuk JUNG [ College of Pharmacy, Seoul National University, Seoul 151-742, South Korea. ]
• Jun Bum PARK [ Dept. of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, 151-742, Korea. ]
• Bokhyeon IM [ College of Pharmacy, Seoul National University, Seoul 151-742, South Korea. ]
• Jin Won SEO [ College of Pharmacy, Seoul National University, Seoul 151-742, South Korea. ]
• Youngro BYUN [ Dept. of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, 151-742, Korea. ]

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  한국생물공학회 학술대회

• 간기

  반년간

• 수록기간

  1985~2013

• 십진분류

  KDC 476 DDC 576